Clinical trials: Sexual Dysfunction
Hypoactive Sexual Desire Disorder
Lybrido for Female Sexual Dysfunction
The Lybrido study is a double-blind, randomized, placebo-controlled study with a 4-week baseline establishment period, 16 week treatment period and a follow up period for a total of 26 weeks on study.
- Trial name
- NCT01432665
- Testing
- Sildenafil, Testosterone
- Where
- 14 sites in United States
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Emotional Brain NY Inc.
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Menopausal Women With Low Libido
This study is designed to evaluate the efficacy and safety of 2 doses of the transdermal testosterone patch in naturally or surgically menopausal women with low libido who are not receiving systemic estrogen or estrogen progestin…
- Trial name
- NCT00131495
- Testing
- Testosterone (transdermal patches)
- Where
- Australia
- Volunteers
- 814 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in surgically menopausal women who are taking estrogen therapy.
- Trial name
- NCT00331123
- Testing
- Testosterone Transdermal System
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 562 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in surgically menopausal women who are taking estrogen therapy.
- Trial name
- NCT00331214
- Testing
- Testosterone Transdermal System
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 533 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
- Trial name
- NCT00338312
- Testing
- Testosterone Transdermal System
- Where
- United States
- Volunteers
- 610 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder (HSDD)
Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
- Trial name
- NCT00349791
- Testing
- Testosterone Transdermal System
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 549 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder
Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen
The purpose of this study is to examine whether the transdermal testosterone system (TTS) is effective and safe in the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women who are on transdermal estrogen.
- Trial name
- NCT00384046
- Testing
- Testosterone
- Where
- 31 sites in Australia, Botswana and 3 more
- Volunteers
- 272 people
- Sponsor
- Warner Chilcott
Erectile Dysfunction, Sexual Dysfunction
Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction
The purpose of this study is to evaluate the efficacy and safety of dapoxetine compared to placebo in men with premature ejaculation and erectile dysfunction who are currently being treated with a phosphodiesterase-5 inhibitor…
- Trial name
- COUPLE (NCT01063855)
- Testing
- Dapoxetine, PDE5I (phosphodiesterase-5 inhibitor)
- Where
- 69 sites in United States, Argentina and 11 more
- Volunteers
- 495 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hypoactive Sexual Desire Disorder
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
This study is a randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of LibiGel® 300mcg in the treatment of HSDD in surgically menopausal women
- Trial name
- BLOOM (NCT00613002)
- Testing
- testosterone gel
- Where
- 63 sites in United States, Canada
- Volunteers
- 597 people
- Sponsor
- BioSante Pharmaceuticals
Hypoactive Sexual Desire Disorder
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
This study is a randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of LibiGel 300mcg in the treatment of HSDD in surgically menopausal women.
- Trial name
- BLOOM (NCT00657501)
- Testing
- testosterone gel
- Where
- 69 sites in United States, Canada
- Volunteers
- 575 people
- Sponsor
- BioSante Pharmaceuticals
Hypoactive Sexual Desire Disorder
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
The objective of this study is to evaluate the persistence of benefit of LibiGel (testosterone gel) 300 mcg/day compared to placebo gel in a 12 week post-treatment period of Hypoactive Sexual Desire Disorder (HSDD) in surgically…
- Trial name
- NCT01235754
- Testing
- transdermal testosterone gel 1%
- Where
- 102 sites in United States, Canada
- Volunteers
- 626 people
- Sponsor
- BioSante Pharmaceuticals
Erectile Dysfunction
A Study to Evaluate Intravaginal Ejaculation Time in Men With and Without Premature Ejaculation
The purpose of the study is to characterize intravaginal ejaculatory latency time (time between the start of vaginal intercourse and the start of intravaginal ejaculation) in men with and without premature ejaculation (PE) and to…
- Trial name
- NCT00210678
- Testing
- No intervention
- Volunteers
- 1,115 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sexual Dysfunctions, Psychological
Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women
To estimate the duration of efficacy with continued treatment of double-blind flibanserin or placebo over twenty-four weeks of treatment.
- Trial name
- NCT00277914
- Testing
- Flibanserin
- Where
- 65 sites in United States, Canada
- Volunteers
- 749 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.
- Trial name
- NCT00467259
- Testing
- Testosterone Transdermal System
- Where
- 115 sites in United States
- Volunteers
- 1,271 people
- Sponsor
- Warner Chilcott
Sexual Dysfunction, Ejaculation
A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation
The primary purpose of the study is to assess the possible withdrawal effects after abruptly stopping daily therapy with dapoxetine compared with continuing daily therapy in men with premature ejaculation (PE).
- Trial name
- NCT00210613
- Testing
- Dapoxetine
- Volunteers
- 199 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Erectile Dysfunction
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
- Trial name
- NCT00210704
- Testing
- Dapoxetine
- Volunteers
- 1,067 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Erectile Dysfunction
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
- Trial name
- NCT00229073
- Testing
- dapoxetine
- Volunteers
- 1,116 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hypoactive Sexual Desire Disorder
A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®
The purpose of this study is to determine if the absorption of the testosterone spray is the same as the Intrinsa® Patch.
- Trial name
- NCT01096329
- Testing
- Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Ejaculation
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
- Trial name
- NCT00211107
- Testing
- Dapoxetine
- Volunteers
- 1,294 people
- Sponsor
- Alza Corporation, DE, USA
Ejaculation, Erectile Dysfunction
An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation
The purpose of this study is to evaluate the long-term safety of dapoxetine in men with rapid ejaculation.
- Conditions
- Ejaculation, Erectile Dysfunction, Sexual Dysfunction
- Trial name
- NCT01230762
- Testing
- dapoxetine
- Volunteers
- 1,774 people
- Sponsor
- Alza Corporation, DE, USA